United States Pharmacopeia online
Select Pharmacopoeia
Ciclopirox Olamine
Click to View Image
C12H17NO2·C2H7NO 268.35
2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-, compound with 2-aminoethanol (1:1).
6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone compound with 2-aminoethanol (1:1) [41621-49-2].
» Ciclopirox Olamine contains not less than 97.5 percent and not more than 101.5 percent of ciclopirox olamine (C12H17NO2·C2H7NO).
Packaging and storage— Preserve in tight containers, protected from light. Store between 5 and 25.
USP Reference standards 11 USP Ciclopirox Olamine RS. USP Ciclopirox Related Compound A RS. USP Ciclopirox Related Compound B RS.
Identification, Infrared Absorption 197K.
pH 791: between 8.0 and 9.0, in a mixture with water (1:100).
Residue on ignition 281: not more than 0.1%.
Heavy metals, Method II 231: not more than 0.001%.
Monoethanolamine content— Dissolve about 300 mg, accurately weighed, in 25 mL of glacial acetic acid. Titrate with 0.1 N perchloric acid VS, determining the endpoint potentiometrically. Perform a blank determination and make any necessary correction. Each mL of 0.1 N perchloric acid is equivalent to 6.108 mg of C2H7NO. The content of monoethanolamine (C2H7NO) is not less than 223 mg and not more than 230 mg per g of ciclopirox olamine (C12H17NO2·C2H7NO) found in the Assay.
Related compounds— [NOTE—Carry out the operations avoiding exposure to actinic light. All materials that are in direct contact with Ciclopirox Olamine (e.g., column materials, reagents, solvents, etc.) should contain only very low amounts of extractable metal cations.]
Mobile phase— Prepare a filtered and degassed mixture of an edetate disodium solution (0.96 in 1000), acetonitrile, and glacial acetic acid (770:230:0.1). Make adjustments if necessary (see System Suitability under Chromatography 621).
Rinsing solution— Prepare a mixture of water, acetonitrile, glacial acetic acid, and acetylacetone (500:500:1:1).
Standard stock solution— Dissolve 15 mg of USP Ciclopirox Related Compound A RS and 15 mg of USP Ciclopirox Related Compound B RS, accurately weighed, in 1 mL of acetonitrile and 7 mL of Mobile phase. Dilute the solution thus obtained with Mobile phase to 10.0 mL to obtain a solution having a known concentration of 1.5 mg of each USP Reference Standard per mL.
Standard solution A— Dilute 1.0 mL of Standard stock solution to 200.0 mL with a mixture of Mobile phase and acetonitrile (9:1).
Standard solution B— Dilute 2.0 mL of Standard solution A to 10.0 mL with a mixture of Mobile phase and acetonitrile (9:1).
Test solution— Dissolve 40 mg of Ciclopirox Olamine, accurately weighed, in a mixture of 2 mL of acetonitrile, 20 µL of glacial acetic acid, and 15 mL of Mobile phase. If necessary, use an ultrasonic bath to dissolve. Dilute with Mobile phase to 20.0 mL, and mix.
Resolution solution— Mix 5 mL of Standard stock solution with 5 mL of the Test solution.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a detector capable of recording at both 220 nm and 298 nm and a 4.0-mm × 8-cm column that contains packing L10. [NOTE—Ciclopirox related compound A has an intense absorbance at 220 nm, and 6-cyclohexyl-4-methyl-2(1H)-pyridone, ciclopirox related compound B, and ciclopirox have intense absorbances at 298 nm.] The flow rate is about 0.7 mL per minute. Chromatograph the Resolution solution at 298 nm, and record the peak responses as directed for Procedure: the resolution, R, between the ciclopirox related compound B peak and the ciclopirox peak is not less than 2.0. Chromatograph Standard solution B at 298 nm, and record the peak responses as directed for Procedure: the chromatogram obtained shows at 298 nm a peak corresponding to ciclopirox related compound B with a signal-to-noise ratio of not less than 3. Chromatograph the Test solution at 298 nm, and record the peak responses as directed for Procedure: the tailing factor for the ciclopirox peak is less than 2.0.
Procedure— Separately inject equal volumes (about 10 µL) of Standard solution A, Standard solution B, and the Test solution into the chromatograph, and record the chromatograms. [NOTE—In order to ensure desorption of disruptive metal ions, every new column must be rinsed with the Rinsing solution over a period of not less than 15 hours and then with Mobile phase for not less than 5 hours with a flow rate of 0.2 mL per minute. The chromatographic run time is not less than 2.5 times the retention time of the ciclopirox peak.] The relative retention times are about 0.5 for ciclopirox related compound A, 0.9 for 6-cyclohexyl-4-methyl-2(1H)-pyridone, 1.0 for ciclopirox, and 1.3 for ciclopirox related compound B. The peak response at 220 nm of the ciclopirox related compound A peak in the chromatogram obtained from the Test solution is not more than the peak response at 220 nm of the corresponding peak in the chromatogram obtained from Standard solution A (0.5% with reference to ciclopirox). The sum of responses at 298 nm of the impurity peaks in the chromatogram obtained from the Test solution is not more than the peak response at 298 nm of the ciclopirox related compound B peak in the chromatogram obtained from Standard solution A (0.5% with reference to ciclopirox). At 298 nm disregard any peak due to the solvent and any peak with a response less than the response of the ciclopirox related compound B peak in the chromatogram obtained from Standard solution B at 298 nm (0.1% with reference to ciclopirox).
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Assay— Dissolve 200 mg of Ciclopirox Olamine, accurately weighed, in 2 mL of methanol. Add 38 mL of water, mix, and titrate with 0.1 N sodium hydroxide VS, determining the endpoint potentiometrically. Perform a blank determination, and make any necessary corrections. Determine the factor of the 0.1 N sodium hydroxide VS using 100 mg of benzoic acid, accurately weighed, and titrate under the conditions prescribed above. Each mL of 0.1 N sodium hydroxide is equivalent to 26.84 mg of ciclopirox olamine (C12H17NO2·C2H7NO).
Auxiliary Information— Staff Liaison : Behnam Davani, Ph.D., MBA, Senior Scientist
Expert Committee : (MDAA05) Monograph Development-Antivirals and Antimicrobials
USP29–NF24 Page 509
Pharmacopeial Forum : Volume No. 30(3) Page 813
Phone Number : 1-301-816-8394